Report topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis
Deadline not yet reached (4 days left)
- Announced
- 6 May 2026
- Due
- 31 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis between August and October 2026”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2 remlifanserin study topline results
- In the company’s control
- High
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-ACAD-002605 · Corrections policy